Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of$ 1.26. This compares to loss of $1.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 1.18 per share when it actually produced a loss of $1.58, delivering a surprise of -33.90%.Over the last four quarters, t ...